Getz Pharma (PVT) Limited, Karachi, Pakistan.
BMC Infect Dis. 2022 May 20;22(1):481. doi: 10.1186/s12879-022-07461-9.
The population-based serosurveys are essential for estimating Coronavirus Disease-19 (COVID-19) burden and monitoring the progression of this pandemic. We aimed to assess the seroprevalence of SARS-CoV-2 antibodies and potential predictors of seropositivity in the Pakistani population.
This population-based seroprevalence study includes consenting subjects from the workplaces (factories, corporates, restaurants, media houses, schools, banks, and hospitals) located in the urban areas of Karachi, Lahore, Multan, Peshawar, and Quetta. We analyzed each subject's serum sample for SARS-CoV-2-IgM and/or IgG antibodies using UNIPER IgG/IgM Rapid COVID-19 Testing Kit. The subject's demographics, exposure history, and symptoms experienced (in last 7 days) were also obtained. The collected data was analyzed using SPSS version 22.0.
The overall seroprevalence of SARS-CoV-2 antibodies was 16.0% (2810/17,764). The total antibody seropositivity was higher in males than females (OR 1.22, 95% CI 1.110-1.340). The symptomatic subjects had 2.18 times higher odds of IgG seropositivity while 1.2 times for IgM seropositivity than the asymptomatic subjects. The multivariable logistic regression model showed that the odds of SARS-CoV-2 total antibody seroprevalence were affected by the number of dependents (OR = 1.077; 95% CI 1.054-1.099), apparent symptomology (OR = 1.288; 95% CI 1.011-1.643), close unprotected contact with a confirmed or probable case of COVID-19 (OR 2.470; 95% CI 2.164-2.819), traveling history (last 14 days) (OR = 1.537; 95% CI 1.234-1.914) and proximity with someone who traveled (OR = 1.534; 95% CI 1.241-1.896).
We found a reasonable seroprevalence of SARS-CoV-2 antibodies in the studied population. Several factors like the number of dependents, apparent symptoms, close unprotected contact with a confirmed or probable case of COVID-19, traveling history, and proximity with someone who traveled are associated with increased odds of SARS-CoV-2 antibody seropositivity.
基于人群的血清学调查对于估计 2019 冠状病毒病（COVID-19）负担和监测该大流行的进展至关重要。我们旨在评估 SARS-CoV-2 抗体在巴基斯坦人群中的血清流行率和潜在的阳性预测因素。
本项基于人群的血清学流行率研究包括来自卡拉奇、拉合尔、木尔坦、白沙瓦和奎达的城市地区工作场所（工厂、公司、餐馆、媒体、学校、银行和医院）的同意参与者。我们使用 UNIPER IgG/IgM 快速 COVID-19 检测试剂盒分析每位受试者血清样本中的 SARS-CoV-2-IgM 和/或 IgG 抗体。还获取了受试者的人口统计学资料、接触史和（过去 7 天内）经历的症状。使用 SPSS 版本 22.0 分析收集的数据。
SARS-CoV-2 抗体的总血清流行率为 16.0%（2810/17764）。男性的总抗体阳性率高于女性（OR 1.22，95%CI 1.110-1.340）。有症状的受试者 IgG 抗体阳性的可能性比无症状受试者高 2.18 倍，IgM 抗体阳性的可能性高 1.2 倍。多变量逻辑回归模型显示，SARS-CoV-2 总抗体血清流行率受受抚养人数（OR=1.077；95%CI 1.054-1.099）、明显症状学（OR=1.288；95%CI 1.011-1.643）、与确诊或疑似 COVID-19 病例的密切无保护接触（OR 2.470；95%CI 2.164-2.819）、旅行史（过去 14 天）（OR=1.537；95%CI 1.234-1.914）和与旅行的人接近（OR=1.534；95%CI 1.241-1.896）的影响。
我们在研究人群中发现了 SARS-CoV-2 抗体的合理血清流行率。受抚养人数、明显症状、与确诊或疑似 COVID-19 病例的密切无保护接触、旅行史以及与旅行的人接近等因素与 SARS-CoV-2 抗体血清阳性率的增加有关。
